Leerink Partnrs Forecasts Stronger Earnings for AstraZeneca

AstraZeneca PLC (NASDAQ:AZN) – Analysts at Leerink Partnrs upped their Q4 2025 earnings per share (EPS) estimates for shares of AstraZeneca in a research report issued to clients and investors on Sunday, November 9th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of $1.18 for the quarter, up from their previous forecast of $1.11. The consensus estimate for AstraZeneca’s current full-year earnings is $4.51 per share.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. The business had revenue of $15.19 billion during the quarter, compared to analysts’ expectations of $14.75 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.08 EPS.

AZN has been the topic of several other reports. Jefferies Financial Group assumed coverage on shares of AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating on the stock. Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, October 16th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $86.00.

AstraZeneca Stock Performance

NASDAQ:AZN opened at $88.61 on Wednesday. The stock’s 50-day moving average is $81.98 and its 200-day moving average is $76.04. AstraZeneca has a 1-year low of $61.24 and a 1-year high of $89.43. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. The stock has a market cap of $274.82 billion, a P/E ratio of 33.31, a price-to-earnings-growth ratio of 1.52 and a beta of 0.34.

Hedge Funds Weigh In On AstraZeneca

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its holdings in shares of AstraZeneca by 30.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock worth $1,003,124,000 after buying an additional 3,224,251 shares in the last quarter. Bank of Montreal Can increased its stake in shares of AstraZeneca by 344.6% in the 3rd quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock valued at $266,841,000 after acquiring an additional 2,695,793 shares in the last quarter. Fayez Sarofim & Co lifted its position in shares of AstraZeneca by 173.4% during the 2nd quarter. Fayez Sarofim & Co now owns 3,745,902 shares of the company’s stock valued at $261,764,000 after acquiring an additional 2,376,032 shares during the period. Valeo Financial Advisors LLC boosted its stake in AstraZeneca by 14,797.3% during the second quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock worth $162,306,000 after acquiring an additional 2,307,047 shares in the last quarter. Finally, Acadian Asset Management LLC grew its holdings in AstraZeneca by 2,389.9% in the second quarter. Acadian Asset Management LLC now owns 2,043,850 shares of the company’s stock worth $142,798,000 after purchasing an additional 1,961,764 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.